Arbios bags $4.8m for Sepet trials:
This article was originally published in Clinica
Waltham, Massachusetts-based biomedical device and cell therapy company Arbios is another step closer to taking its Sepet liver assist device to market, having pocketed $4.8m from a private placement of stocks and warrants. MicroCapital led the financing round. The proceeds will enable the company to go ahead with plans for CE-marking the Sepet, as well as initiating pivotal clinical trials of the device to support its application for US approval. Arbios' Sepet liver assist device, designed for use with standard blood dialysis systems, helps to purify the blood of patients with chronic liver failure caused by hepatitis B, hepatitis C or alcoholic cirrhosis.